Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR Analysis

优化患者选择以降低减低强度预处理后的非复发死亡率:CIBMTR 分析

阅读:1

Abstract

BACKGROUND: Reduced-intensity conditioning (RIC) is generally associated with lower nonrelapse mortality (NRM) but higher relapse risk compared to myeloablative conditioning (MAC) in allogeneic hematopoietic cell transplantation (HCT). The Risk assessment for the Intensity of Conditioning regimen in Elderly patients (RICE) score, developed using a large Japanese cohort, was designed to identify patients likely to benefit from reduced NRM with RIC. It is calculated based on three factors: advanced age, high comorbidities, and use of umbilical cord blood donor. PURPOSE: In this study, we evaluated the applicability of the RICE score in a Western population using a publicly available CIBMTR dataset. STUDY DESIGN: This study included 2595 patients aged 40 to 65 years with AML and MDS who underwent their first HCT between 2009 and 2015. The primary endpoint was NRM, stratified by conditioning intensity and RICE score. RESULTS: Among patients with a low RICE score, MAC was associated with similar NRM (HR, 0.86; 95% CI, 0.70 to 1.06; P = .150) but lower relapse, resulting in improved disease-free survival (DFS). In contrast, among patients with a high RICE score, NRM was significantly lower with RIC compared to MAC (HR, 0.69; 95% CI, 0.48 to 0.99; P = .048), while DFS was similar due to a higher relapse rate with RIC. CONCLUSION: This study provides external validation of the RICE score in a Western cohort and suggests its potential to inform conditioning-intensity selection based on individual patient characteristics. This simple, data-driven tool may help accurately assess the risk of NRM associated with conditioning intensity and improve transplant outcomes across diverse populations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。